Stroke of undetermined cause: workup and secondary prevention.

PURPOSE OF REVIEW The purpose of this review is to update the reader on current concepts of workup and secondary prevention in patients with stroke of undetermined cause. RECENT FINDINGS Clinical research in patients with cryptogenic stroke has been hampered by the lack of standardized, widely accepted diagnostic criteria. The new definition of 'Embolic stroke of undetermined etiology' postulates an embolic mechanism of ischemic stroke. It is based on the exclusion of lacunar infarction by brain imaging, arterial stenosis more than 50% or dissection of the respective brain-supplying artery by computed tomography/magnetic resonance-angiography or ultrasound, atrial fibrillation by at least 24 h EKG monitoring, as well as some rare etiologies such as vasculitis, drug abuse, or coagulopathies. However, it still comprises many patients with atherosclerotic etiologies (but <50% stenosis) as well as covert paroxysmal atrial fibrillation which can be detected by repeated Holter EKG or an implantable device. A patent foramen ovale can be found in up to 58% of cryptogenic stroke patients, but causality in an individual patient remains uncertain and can only be statistically inferred. SUMMARY The new concept of embolic stroke of undetermined etiology enabled three ongoing randomized controlled trials which investigate oral anticoagulation versus aspirin for secondary stroke prevention.

[1]  K. Furie,et al.  Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. , 2008, Stroke.

[2]  V. Hachinski,et al.  Very Short Paroxysms Account for More Than Half of the Cases of Atrial Fibrillation Detected after Stroke and TIA: A Systematic Review and Meta-Analysis , 2015, International journal of stroke : official journal of the International Stroke Society.

[3]  Frank Beckers,et al.  Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.

[4]  K. Furie,et al.  A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. , 2001, The New England journal of medicine.

[5]  J. Carroll,et al.  Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. , 2013, The New England journal of medicine.

[6]  G. Schuler,et al.  Percutaneous closure of patent foramen ovale in cryptogenic embolism. , 2013, The New England journal of medicine.

[7]  Shinichiro Uchiyama,et al.  Ulcerated carotid plaques with ultrasonic echolucency are causatively associated with thromboembolic cerebrovascular events. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[8]  M. Reiser,et al.  Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. , 2012, JACC. Cardiovascular imaging.

[9]  D. Blacker,et al.  Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques , 2014, Stroke.

[10]  R. Sacco,et al.  Comparison of Warfarin versus Aspirin for the Prevention of Recurrent Stroke or Death: Subgroup Analyses from the Warfarin-Aspirin Recurrent Stroke Study , 2006, Cerebrovascular Diseases.

[11]  David J Gladstone,et al.  Atrial fibrillation in patients with cryptogenic stroke. , 2014, The New England journal of medicine.

[12]  M. Hennerici,et al.  The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping) , 2013, Cerebrovascular Diseases.

[13]  A. Hennemuth,et al.  Prevalence of Potential Retrograde Embolization Pathways in the Proximal Descending Aorta in Stroke Patients and Controls , 2014, Cerebrovascular Diseases.

[14]  Letter by Mahagne et al regarding article, "Embolic strokes of undetermined source in the athens stroke registry: a descriptive analysis". , 2015, Stroke.

[15]  E. Zanette,et al.  Detection of Right-to-Left Shunt with Ultrasound Contrast Agent and Transcranial Doppler Sonography , 2000, Cerebrovascular Diseases.

[16]  H. Diener,et al.  Current Management and Risk of Recurrent Stroke in Cerebrovascular Patients with Right-to-Left Cardiac Shunt , 2009, Cerebrovascular Diseases.

[17]  S. Connolly,et al.  Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.

[18]  M. O’Donnell,et al.  Transesophageal echocardiography in patients with cryptogenic ischemic stroke: a systematic review. , 2014, American heart journal.

[19]  A. Capucci,et al.  Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events , 2014, Circulation.

[20]  Eric E. Smith,et al.  Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014 , 2015, International journal of stroke : official journal of the International Stroke Society.

[21]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[22]  A. Meretoja,et al.  Undetermined stroke with an embolic pattern—a common phenotype with high early recurrence risk , 2015, Annals of medicine.

[23]  P. Irimia,et al.  Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico , 2014 .

[24]  H. Milionis,et al.  Embolic Strokes of Undetermined Source in the Athens Stroke Registry: An Outcome Analysis , 2015, Stroke.

[25]  Olaf Gefeller,et al.  Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria: Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study , 2001, Stroke.

[26]  C. O'connor,et al.  Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial , 2009, Circulation.

[27]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[28]  H. Diener,et al.  Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies , 2009, Cerebrovascular Diseases.

[29]  G. Lip,et al.  Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial , 2014, Cerebrovascular Diseases.

[30]  R. Adams,et al.  Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. , 1951, Journal of neuropathology and experimental neurology.

[31]  D. Kent,et al.  An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke , 2013, Neurology.

[32]  M. Hennerici,et al.  New Approach to Stroke Subtyping: The A-S-C-O (Phenotypic) Classification of Stroke , 2009, Cerebrovascular Diseases.

[33]  A. Algra,et al.  Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial , 2007, The Lancet Neurology.

[34]  Chun Yuan,et al.  Classification of Human Carotid Atherosclerotic Lesions With In Vivo Multicontrast Magnetic Resonance Imaging , 2002, Circulation.

[35]  J. Martí-Fàbregas,et al.  Recurrent Stroke and Massive Right-to-Left Shunt: Results From the Prospective Spanish Multicenter (CODICIA) Study , 2008, Stroke.

[36]  J. Coste,et al.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. , 2001, The New England journal of medicine.

[37]  J. Miguel Sanches,et al.  An Ultrasonographic Risk Score For Detecting Symptomatic Carotid Atherosclerotic Plaques , 2015, IEEE Journal of Biomedical and Health Informatics.

[38]  R. Felberg,et al.  Closure or medical therapy for cryptogenic stroke with patent foramen ovale. , 2012, The New England journal of medicine.

[39]  P. Rothwell,et al.  Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study , 2015, The Lancet Neurology.

[40]  W M O'Fallon,et al.  Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. , 2000, Stroke.